New China FDA chief signals pricing reform a priority

A change at the top of China FDA may indicate that drug pricing reform is now a top priority of the government.

China State Council Deputy Secretary-General Bi Jingquan will serve as both CFDA commissioner and secretary-general of the Communist Party, a minister-level position. Bi served for more than a decade at the powerful National Development and Reform Commission (NDRC), China's top economic planning agency under the State Council. In the pharma industry, NDRC is best known for oversight of drug pricing and enforcement of the Anti-Monopoly Law. Bi has been the deputy director of NDRC since 2006, and also served for more than a decade as deputy director of the State Price Bureau. ...